272.74 USD
+5.1 (+1.91%)
At close: Feb 6, 2026
272.74 USD
0 (0%)
After Hours: 2/6/2026, 8:00:02 PM
Overall KRYS gets a fundamental rating of 6 out of 10. We evaluated KRYS against 524 industry peers in the Biotechnology industry. KRYS has an excellent financial health rating, but there are some minor concerns on its profitability. KRYS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- KRYS had positive earnings in the past year.
- KRYS had a positive operating cash flow in the past year.
- In multiple years KRYS reported negative net income over the last 5 years.
- In the past 5 years KRYS reported 4 times negative operating cash flow.
1.2 Ratios
- KRYS has a better Return On Assets (16.04%) than 95.80% of its industry peers.
- Looking at the Return On Equity, with a value of 17.48%, KRYS belongs to the top of the industry, outperforming 95.23% of the companies in the same industry.
- The Return On Invested Capital of KRYS (12.28%) is better than 95.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROIC | 12.28% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- KRYS's Profit Margin of 53.30% is amongst the best of the industry. KRYS outperforms 98.47% of its industry peers.
- KRYS's Operating Margin of 42.40% is amongst the best of the industry. KRYS outperforms 99.24% of its industry peers.
- The Gross Margin of KRYS (94.26%) is better than 94.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- KRYS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- KRYS has more shares outstanding than it did 1 year ago.
- KRYS has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 47.06 indicates that KRYS is not in any danger for bankruptcy at the moment.
- The Altman-Z score of KRYS (47.06) is better than 96.37% of its industry peers.
- KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 47.06 |
ROIC/WACC1.39
WACC8.86%
2.3 Liquidity
- KRYS has a Current Ratio of 10.14. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 10.14, KRYS belongs to the top of the industry, outperforming 81.30% of the companies in the same industry.
- KRYS has a Quick Ratio of 9.73. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
- KRYS's Quick ratio of 9.73 is amongst the best of the industry. KRYS outperforms 80.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 276.84% over the past year.
- Looking at the last year, KRYS shows a very strong growth in Revenue. The Revenue has grown by 54.51%.
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
3.2 Future
- Based on estimates for the next years, KRYS will show a very strong growth in Earnings Per Share. The EPS will grow by 58.10% on average per year.
- The Revenue is expected to grow by 31.67% on average over the next years. This is a very strong growth
EPS Next Y114.44%
EPS Next 2Y64.64%
EPS Next 3Y46.4%
EPS Next 5Y58.1%
Revenue Next Year34.01%
Revenue Next 2Y38.02%
Revenue Next 3Y36.66%
Revenue Next 5Y31.67%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 40.89, which means the current valuation is very expensive for KRYS.
- Based on the Price/Earnings ratio, KRYS is valued cheaply inside the industry as 91.60% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of KRYS to the average of the S&P500 Index (27.92), we can say KRYS is valued slightly more expensively.
- With a Price/Forward Earnings ratio of 33.65, KRYS can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, KRYS is valued cheaper than 91.41% of the companies in the same industry.
- KRYS's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.78.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.89 | ||
| Fwd PE | 33.65 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaply inside the industry as 91.60% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 92.75% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.77 | ||
| EV/EBITDA | 41 |
4.3 Compensation for Growth
- KRYS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of KRYS may justify a higher PE ratio.
- KRYS's earnings are expected to grow with 46.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y64.64%
EPS Next 3Y46.4%
5. Dividend
5.1 Amount
- No dividends for KRYS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
272.74
+5.1 (+1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners96.44%
Inst Owner Change-1.97%
Ins Owners11.65%
Ins Owner Change-1.32%
Market Cap7.91B
Revenue(TTM)373.16M
Net Income(TTM)198.91M
Analysts84.44
Price Target296.64 (8.76%)
Short Float %10.74%
Short Ratio8.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.19%
Min EPS beat(2)12.14%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)41.54%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)30.53%
EPS beat(12)5
Avg EPS beat(12)2.39%
EPS beat(16)7
Avg EPS beat(16)0.53%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.42%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)4
Avg Revenue beat(8)4.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.96%
PT rev (3m)22.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.24%
EPS NY rev (1m)2.63%
EPS NY rev (3m)25.87%
Revenue NQ rev (1m)1.17%
Revenue NQ rev (3m)1.52%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)1.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.89 | ||
| Fwd PE | 33.65 | ||
| P/S | 21.2 | ||
| P/FCF | 47.77 | ||
| P/OCF | 44.89 | ||
| P/B | 6.95 | ||
| P/tB | 6.95 | ||
| EV/EBITDA | 41 |
EPS(TTM)6.67
EY2.45%
EPS(NY)8.1
Fwd EY2.97%
FCF(TTM)5.71
FCFY2.09%
OCF(TTM)6.08
OCFY2.23%
SpS12.87
BVpS39.24
TBVpS39.24
PEG (NY)0.36
PEG (5Y)N/A
Graham Number76.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROCE | 13.77% | ||
| ROIC | 12.28% | ||
| ROICexc | 33.76% | ||
| ROICexgc | 33.76% | ||
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% | ||
| FCFM | 44.37% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 213.54% | ||
| Cap/Sales | 2.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 107.96% | ||
| Profit Quality | 83.25% | ||
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 | ||
| Altman-Z | 47.06 |
F-Score7
WACC8.86%
ROIC/WACC1.39
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
EPS Next Y114.44%
EPS Next 2Y64.64%
EPS Next 3Y46.4%
EPS Next 5Y58.1%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
Revenue Next Year34.01%
Revenue Next 2Y38.02%
Revenue Next 3Y36.66%
Revenue Next 5Y31.67%
EBIT growth 1Y143.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year182.48%
EBIT Next 3Y83.71%
EBIT Next 5YN/A
FCF growth 1Y239.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.59%
OCF growth 3YN/A
OCF growth 5YN/A
KRYSTAL BIOTECH INC / KRYS FAQ
Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?
ChartMill assigns a fundamental rating of 6 / 10 to KRYS.
What is the valuation status for KRYS stock?
ChartMill assigns a valuation rating of 6 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Fairly Valued.
What is the profitability of KRYS stock?
KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for KRYS stock?
The Price/Earnings (PE) ratio for KRYSTAL BIOTECH INC (KRYS) is 40.89 and the Price/Book (PB) ratio is 6.95.
What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?
The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 9 / 10.